• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

VC shops back CeloNova BioSciences

August 7, 2017 By Sarah Faulkner

Celonova BiosciencesCeloNova BioSciences said today that it inked a 4-year financing deal with Congruent Investment Partners and SWK Holdings Corp.

The funds are slated to support CeloNova’s ongoing clinical trials and product initiatives, including the launch of its Cobra PzF NanoCoated coronary stent.

The device, which won FDA approval this year, is designed to treat patients with symptomatic ischemic heart disease. The Cobra PzF NCS requires patients to undergo at least one month of dual antiplatelet therapy following treatment, according to CeloNova.

“We are pleased to partner with CeloNova. CeloNova has proven to be an innovator in developing high quality biocompatible products using its proprietary Polyzene-F nano-thin polymer,” Congruent co-founder Travis Baldwin said in prepared remarks. “We are confident that CeloNova is well positioned to gain market share within the interventional cardiology industry.”

“We are impressed with the quality and depth of CeloNova’s management team and its latest innovative product,” SWK CEO Winston Black added. “The Cobra PzF NCS is an important addition to the interventional cardiology marketplace and should provide physicians a clear choice for treating patients with coronary artery disease.”

“Following FDA approval of the Cobra PzF NCS in February 2017, we are continuing to move forward with our national commercialization efforts. This financial agreement provides us with the necessary capital to bolster our overall growth and expansion in the U.S. marketplace,” CeloNova CEO Jason Cone said. “It’s an exciting time for CeloNova and we thank both Congruent Investment Partners and SWK Holdings for their steadfast support.”

The company’s Cobra Reduce trial, which began enrolling patients in February last year, is comparing CeloNova’s stent to drug-eluting stents in patients with coronary artery disease who are at high risk for bleeding.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

 

Filed Under: Cardiovascular, Clinical Trials, Featured, Funding Roundup, Wall Street Beat Tagged With: celonova

IN CASE YOU MISSED IT

  • Abbott will spend $450M to up FreeStyle Libre production in Ireland
  • Better Therapeutics Q2 beats Street as it prepares to submit diabetes therapy for FDA review
  • Study backs Fluidx embolic device for vessel filling
  • Senseonics stock is up as it sticks by revenue guidance
  • Rapid Dose closes first tranche of $5M financing

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS